Evidence map›Paper›PMID 36299398›Full record

ArticleGynecologic oncology reports2022

Multisite gynecologic endometrioid adenocarcinomas: Can mutation profiling be used to distinguish synchronous primary cancers from metastases?

Dominique Barnes, Nissreen Mohammad, Lien Hoang, Michael Anglesio, Robert L Hollis, Charlie Gourley, Heather C Stuart, Mark S Carey, Gavin C E Stuart

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Gynecologic oncology reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Dominique BarnesDepartment of Obstetrics and Gynecology, University of British Columbia, Canada.
Nissreen MohammadDepartment of Pathology, Vancouver General Hospital and the University of British Columbia, Canada.
Lien HoangDepartment of Pathology, Vancouver General Hospital and the University of British Columbia, Canada.
Michael AnglesioDepartment of Obstetrics and Gynecology, University of British Columbia, Canada.
Robert L HollisThe Nicola Murray Centre for Ovarian Cancer Research, Cancer Research UK Scotland Centre, MRC Institute of Genetics and Cancer, University of Edinburgh, UK.
Charlie GourleyThe Nicola Murray Centre for Ovarian Cancer Research, Cancer Research UK Scotland Centre, MRC Institute of Genetics and Cancer, University of Edinburgh, UK.
Heather C StuartDepartment of Surgery, Vancouver General Hospital, and the University of British Columbia, Canada.
Mark S CareyDepartment of Obstetrics and Gynecology, University of British Columbia, Canada.
Gavin C E StuartDepartment of Obstetrics and Gynecology, University of British Columbia, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

It is well recognized that some patients with endometrioid gynecological cancers have tumors arising in multiple sites (ovary, endometrium, and endometriosis) at the time of diagnosis. Molecular analysis has helped discern whether these multisite cancers represent synchronous primary tumors or alternatively metastatic disease. We present a complex case of a patient with endometrioid carcinomas arising in multiple sites. We discuss the use of mutation profiling to discern clonality and highlight how this information may inform the clinical management of such cases.

Indexed as

ClonalityEndometrioid carcinomaGynecologic cancersMutation analysis

Identifiers

PMID36299398
PMCPMC9589011

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.